BCL10 and psoriasis: We then verified the possibility that the inability of CARMA2shE138A and CARMA2shE142G to promote degradation of BCL10 was somehow associated with their higher capacity to activate NF-κB. For this, we tested an additional psoriasis-linked mutant, CARMA2shR38C, which is incapable to activate NF-κB.6 However, as shown in Supplementary Figure 4, also CARMA2shR38C is unable to support degradation of BCL10.